Kynam Capital Management, LP Beam Therapeutics Inc. Transaction History
Kynam Capital Management, LP
- $1.19 Billion
- Q1 2025
A detailed history of Kynam Capital Management, LP transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Kynam Capital Management, LP holds 2,518,170 shares of BEAM stock, worth $46.1 Million. This represents 4.14% of its overall portfolio holdings.
Number of Shares
2,518,170
Previous 1,756,158
43.39%
Holding current value
$46.1 Million
Previous $43.6 Million
12.92%
% of portfolio
4.14%
Previous 2.76%
Shares
3 transactions
Others Institutions Holding BEAM
# of Institutions
247Shares Held
94.7MCall Options Held
425KPut Options Held
309K-
Farallon Capital Management LLC San Francisco, CA9.93MShares$182 Million1.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.87MShares$162 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.85MShares$162 Million1.24% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$140 Million0.0% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.4.73MShares$86.5 Million0.05% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $1.29B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...